• Publications
  • Influence
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
TLDR
The PK and safety profiles of erlotinib in patients with MHI were similar to those with AHF and treatment should be guided by patients’ tolerability.
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
TLDR
The all-oral combination of the two drugs offers the potential for targeting angiogenesis in capecitabine-sensitive tumors with nonoverlapping toxicities and was well tolerated, without any consistent pattern of drug-related grade 3 or grade 4 toxicities being observed.
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
TLDR
These results indicate that RPI.4610, carboplatin, and paclitaxel can be administered safely in combination without substantial pharmacokinetic interactions.
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
TLDR
TAK-960 is an active anti-proliferative agent against CRC cell lines and PDX models and may be of therapeutic benefit alone or in combination with other agents, although future work should focus on the development of predictive biomarkers and hypothesis-driven rational combinations.